20-30% of patients experiencing relapse after first-line treatment
Standard of care therapies for DLBCL have suboptimal results, with 20-30% of patients experiencing relapse after first-line treatment. Additionally, existing therapies may cause serious adverse events such as cytokine release syndrome.
Bantam Pharmaceuticals is developing an IND-cleared candidate, BNTM-3566, which takes advantage of a DLBCL-specific vulnerabilities to activate cellular stress and tumor apoptosis pathways.
USD 5B market
Bantam Pharmaceuticals is initially targeting the DLBCL market, which has a total market opportunity of ~$5B.
"We are excited to see how BTM-3566 promoted complete tumor regression in vivo in mouse models with poor prognosis. We believe BTM-3566's mechanism of action potentially defines a new class of compounds that activate, and regulate, the mitochondrial protease OMA1.”
Adrian Schwarzer, M.D., Ph.D (Resident at the Department of Hematology, Oncology and Stem Cell Transplantation, Hannover Medical School)